sorafenib has been researched along with Lung Adenocarcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, JB; Briggs, DC; Carlomagno, F; Frett, B; Kharbanda, A; Knowles, P; Lakkaniga, NR; Leung, YK; Li, HY; McDonald, NQ; Moccia, M; Santoro, M; Tran, P; Wang, X; Yan, W; Zhang, L | 1 |
| Amos, C; Cheng, C; Schaafsma, E; Weng, YL; Zhao, Y | 1 |
| Hsieh, CY; Hua, KF; Ju, TC; Li, LH; Pivkin, MV; Rao, YK; Wong, WT; Wu, HY; Wu, SH; Yang, FL | 1 |
| Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA | 1 |
| Dudek, A; Konety, SH; Masri, SC; Misselt, AJ | 1 |
| Chen, XQ; Li, ZY; Lin, TY; Wang, YL | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
7 other study(ies) available for sorafenib and Lung Adenocarcinoma
| Article | Year |
|---|---|
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Topics: Adenocarcinoma of Lung; Apoptosis; Cell Proliferation; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured; Wound Healing | 2022 |
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Datasets as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Liver Neoplasms; Logistic Models; Lung Neoplasms; Models, Genetic; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; RNA-Seq; Signal Transduction; Sorafenib; Transcriptome | 2020 |
Ergosterol peroxide from marine fungus Phoma sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Apoptosis; Aquatic Organisms; Autophagy; Cell Line, Tumor; Cell Survival; Drug Synergism; Ergosterol; Fungi; Humans; Inflammasomes; Molecular Structure; NLR Family, Pyrin Domain-Containing 3 Protein; Reactive Oxygen Species; Sorafenib; Tumor Stem Cell Assay | 2018 |
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA, Neoplasm; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Sorafenib | 2014 |
Radiation recall reaction causing cardiotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Chemoradiotherapy; Coronary Angiography; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiation Dosage; Radiation Injuries; Risk Factors; Sorafenib; Whole Body Imaging | 2014 |
Therapeutic effects of sorafenib on the A549/DDP human lung adenocarcinoma cell line in vitro.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |